New Treatment for Endometrial Cancer Shows Promise

Drugmaker Merck has announced promising results from a Phase 3 clinical trial for a new treatment targeting endometrial cancer. The investigational drug, sacituzumab tirumotecan (sac-TMT), achieved its primary goals of improving overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.

The TroFuse-005 trial is significant for being the first global Phase 3 study to demonstrate a statistically significant improvement in survival compared to chemotherapy for these patients. According to Merck, this trial marks the first instance where an antibody-drug conjugate (ADC) has achieved such results for endometrial cancer in this context.

Antibody-drug conjugates are targeted cancer therapies designed to deliver more of the drug to tumor cells, minimizing harm to healthy cells. Sac-TMT is given every two weeks through an IV infusion.

The study involved 776 patients with endometrial cancer that had worsened after initial treatment with platinum chemotherapy and immunotherapy. Participants were randomly assigned either sac-TMT or a physician’s choice of treatment, including doxorubin or paclitaxel chemotherapy.

Patients receiving sac-TMT showed significantly better outcomes in their disease state compared to the other treatment options. The trial met response rate goals and showed side effects similar to previous studies of the drug.

Dr. Domenica Lorusso, a global lead investigator on the study, expressed optimism, stating, “Sac-TMT may be able to meet a critical unmet need for certain patients with advanced endometrial cancer.”

Merck has not yet released detailed statistics on survival benefits or side effects, but researchers plan to present the Phase 3 data at an upcoming medical meeting.

Despite recent therapeutic advances, there remains an urgent need for new treatment options for patients whose disease progresses after initial therapies. Dr. Brian Slomovitz, a co-director of gynecologic oncology at Mount Sinai and a trial investigator, noted the rising incidence and mortality of endometrial cancer compared to other cancers.

Dr. Slomovitz highlighted that endometrial cancer now causes more deaths in the United States than ovarian cancer, making it the deadliest gynecologic malignancy. He emphasized that improved survival in recurrent disease would be a vital outcome for patients and their families.

Further analysis and data from the trial will be crucial in understanding the complete impact and potential role of sac-TMT as a treatment option for advanced endometrial cancer.